{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:25:50Z","timestamp":1793384750916,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk AS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000382","name":"Society for Endocrinology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clinme.2025.100528","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T21:08:22Z","timestamp":1762463302000},"page":"100528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Diabetes and the liver"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6879-6286","authenticated-orcid":false,"given":"Ebo","family":"Dadey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4814-5754","authenticated-orcid":false,"given":"Tiong Yeng","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Makaronidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinme.2025.100528_bib0001","unstructured":"Diabetes UK. Diabetes Prevalence. London: Diabetes UK; 2019 [cited 2025 Jul 25]. Available from: https:\/\/www.diabetes.org.uk\/about-us. Accessed 25 July, 2025."},{"issue":"3","key":"10.1016\/j.clinme.2025.100528_bib0002","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"European association for the study of diabetes, european association for the study of obesity. EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinme.2025.100528_sbref0003","series-title":"StatPearls","article-title":"Biochemistry, insulin metabolic effects","author":"Vargas","year":"2025"},{"issue":"4","key":"10.1016\/j.clinme.2025.100528_bib0004","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"1A","key":"10.1016\/j.clinme.2025.100528_bib0005","doi-asserted-by":"crossref","first-page":"28J","DOI":"10.1016\/S0002-9149(99)00355-0","article-title":"Insulin resistance and lipid metabolism","volume":"84","author":"Howard","year":"1999","journal-title":"Am J Cardiol"},{"issue":"Suppl","key":"10.1016\/j.clinme.2025.100528_bib0006","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"10.1016\/j.clinme.2025.100528_bib0007","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/hep.30858","article-title":"Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease","volume":"71","author":"Yang","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.clinme.2025.100528_bib0008","doi-asserted-by":"crossref","first-page":"5","DOI":"10.17925\/EE.2024.20.2.2","article-title":"Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: a deadly synergy","volume":"20","author":"Leith","year":"2024","journal-title":"touchREV Endocrinol"},{"issue":"3","key":"10.1016\/j.clinme.2025.100528_bib0009","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review","volume":"32","author":"Chan","year":"2023","journal-title":"J Obes Metab Syndr"},{"key":"10.1016\/j.clinme.2025.100528_bib0010","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/5202684","article-title":"Diabetes mellitus and risk of hepatocellular carcinoma","volume":"2017","author":"Li","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.clinme.2025.100528_sbref0011","series-title":"Type 2 Diabetes in Adults: Management (NICE Guideline NG28)","year":"2022"},{"key":"10.1016\/j.clinme.2025.100528_sbref0012","series-title":"Non Alcoholic Fatty Liver Disease (NAFLD): Assessment and Management (NICE guideline NG49)","year":"2016"},{"issue":"1","key":"10.1016\/j.clinme.2025.100528_bib0013","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2017-314924","article-title":"Guidelines on the management of abnormal liver blood tests","volume":"67","author":"Newsome","year":"2018","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.clinme.2025.100528_bib0014","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jceh.2021.09.010","article-title":"An approach to the management of diabetes mellitus in cirrhosis: a primer for the hepatologist","volume":"12","author":"Puri","year":"2022","journal-title":"J Clin Exp Hepatol"},{"issue":"7","key":"10.1016\/j.clinme.2025.100528_bib0015","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1210\/js.2017-00183","article-title":"Diagnosis and clinical implications of diabetes in liver cirrhosis: a focus on the oral glucose tolerance test","volume":"1","author":"Nishida","year":"2017","journal-title":"J Endocr Soc"},{"issue":"3","key":"10.1016\/j.clinme.2025.100528_bib0016","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2337\/diaclin.23.3.115","article-title":"Elevated liver function tests in type 2 diabetes","volume":"23","author":"Harris","year":"2005","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.clinme.2025.100528_sbref0017","series-title":"MASLD, NAFLD and Fatty Liver Disease","year":"2024"},{"issue":"1","key":"10.1016\/j.clinme.2025.100528_bib0018","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/30502071231220779","article-title":"Diagnosis and management of MASLD: a metabolic perspective of a multisystem disease","volume":"1","author":"Ganakumar","year":"2024","journal-title":"Internat J Clin Metab Diabetes"},{"issue":"2","key":"10.1016\/j.clinme.2025.100528_bib0019","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4093\/dmj.2019.0034","article-title":"Nonalcoholic fatty liver disease and diabetes: part II: treatment","volume":"43","author":"Kim","year":"2019","journal-title":"Diabetes Metab J"},{"issue":"9","key":"10.1016\/j.clinme.2025.100528_bib0020","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.clinme.2025.100528_bib0021","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.clinme.2025.100528_bib0022","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clinme.2025.100528_bib0023","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.clinme.2025.100528_bib0024","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinme.2025.100528_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.769069","article-title":"Efficacy and safety of GLP-1 receptor agonists in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.clinme.2025.100528_bib0026","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10403","key":"10.1016\/j.clinme.2025.100528_bib0027","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clinme.2025.100528_bib0028","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinme.2025.100528_bib0029","first-page":"1179","article-title":"Resmetirom in metabolic dysfunction\u2013associated steatohepatitis: results from the phase 3 MAESTRO-NASH trial","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clinme.2025.100528_bib0030","article-title":"Antifibrotic therapies for metabolic dysfunction\u2013associated steatotic liver disease","volume":"7","author":"Schwabe","year":"2025","journal-title":"JHEP Rep"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211825002465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211825002465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:37:38Z","timestamp":1769161058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211825002465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1470211825002465"],"URL":"https:\/\/doi.org\/10.1016\/j.clinme.2025.100528","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetes and the liver","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinme.2025.100528","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of Royal College of Physicians.","name":"copyright","label":"Copyright"}],"article-number":"100528"}}